Illumina Introduces a New Genomic Era
Illumina's (NASDAQ: ILMN) second-quarter earnings crushed expectations last week. Investors cheered the company's raised guidance, and the stock is up more than 15% since the report.
Illumina's genomic sequencing machines read the As, Cs, Ts, and Gs of a human being's DNA and then digitizes them into a format that can be easily understood. One of the most exciting developments in the company's recent history was the introduction earlier this year of its newest NovaSeq model. NovaSeq has the potential to bring the cost of a human genome sequence down to $100, which would be a tenfold reduction from where we stand today.
This lower cost of sequencing has profound implications for the company and its investors, but also the entire medical community. Let's take a closer, DNA-level look at what this could really mean.
Source: Fool.com
Illumina Inc. Stock
The stock is one of the favorites of our community with 28 Buy predictions and 4 Sell predictions.
As a result the target price of 161 € shows a positive potential of 42.43% compared to the current price of 113.04 € for Illumina Inc..
